Inventaire - your friends and communities are your best library

Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration

published in: Drugs & Aging

date of publication: 2013-05-01

language: English

Cites articles 103

Date

Title

Authors

2012-01-01

The expanding role of vascular endothelial growth factor inhibitors in ophthalmology
2012-05-01

Preferred therapies for neovascular age-related macular degeneration
2012-10-01

Aflibercept for intravitreal injection: in neovascular age-related macular degeneration
2012-01-24

Bevacizumab for the treatment of neovascular age-related macular degeneration
2012-03-01

Ranibizumab: in diabetic macular oedema
2012-06-01

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
2012-07

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Cynthia A Toth
2012-05-11

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

Paul Bishop
2012-07-19

Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans.

Tim U. Krohne, Zengping Liu, Frank G Holz
2012-09-23

Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab

Paul P. Lee
2012-10-17

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration

Ngaihang Victor Chong, Christian Simader, Peter K Kaiser, Ursula Schmidt-Erfurth, Yuichiro Ogura, Neil Stahl, Robert Vitti, Alyson J Berliner, Yuhwen Soo, Majid Anderesi, Rupert Sandbrink
2012-09-25

The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration

Ruth Axer-Siegel, Robyn H. Guymer
2012-01-30

Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.

Kostas Athanasakis
2012-02-06

Ranibizumab for age-related macular degeneration

Peter K Kaiser
2012-09-27

Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment
2012-09-21

Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration
2012-09-01

EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy

Timothy Y Y Lai
2012-08-12

Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines

Peter K Kaiser, Kamlesh Khunti, S P Kelly
2012-06-01

Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections
2012-02-01

Effectiveness at 1 year of monthly versus variable-dosing intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to age-related macular degeneration

Filiberto Altomare
2012-02-04

HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration
2012-03-22

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study

Peter K Kaiser
2012-10-01

Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials

Neil M. Bressler
2012-02-28

Anti-VEGF Treatment Strategies for Wet AMD.

Harry W Flynn, Ingrid U. Scott, Stephen G Schwartz, Jaclyn L Kovach
2012-08-22

Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab
2012-01-01

Age-related macular degeneration

Jocelyn Cherry, Andrew J Lotery
2012-03-17

Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results

Michael Larsen, Ursula Schmidt-Erfurth, Sebastian Wolf, Christian Simader
2011-04-08

Comparing protein VEGF inhibitors: In vitro biological studies.

Napoleone Ferrara
2011-05-19

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Glenn Jaffe
2011-08-27

Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration
2011-06-25

Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents
2011-09-01

Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration

Ciro Costagliola, Francesco Semeraro, Barbara Arcidiacono, Francesco Parmeggiani

Article - wd:Q38094076

Welcome to Inventaire

the library of your friends and communities

learn more